Jak Kinase Pathway Inhibitor Drugs in Patients With Moderate-to-Severe Alopecia: A Real-World Experience

This study assessed the effectiveness and safety of baricitinib, a JAK kinase pathway inhibitor, in 24 patients with moderate-to-severe alopecia areata in a real-world setting. The results showed a 62.5% response rate after 52 weeks, with 29% achieving complete hair regrowth. Baricitinib was well-tolerated, with mild adverse reactions such as herpes simplex and headaches, and no severe adverse events leading to discontinuation. The study concludes that baricitinib is a promising treatment for alopecia areata, although further research with larger sample sizes is necessary to confirm these findings.